Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium A. R. Sousa, I. Pandis, Y. Xian, U. Hoda, A. Rowe, J. Corfield, E. Jeyasingham, A. Bansal, W. Seibold, A. Wagener, P. Bakke, G. Roberts, F. Singer, U. Frey, H. Ildikó, R. Polosa, N. Krug, R. Middelveld, S. E. Dahlen, J. Musial, D. Gibeon, L. Fleming, S. Fowler, L. Pahus, D. Shaw, P. Howarth, D. Myles, C. Compton, T. Higenbottam, P. Montuschi, J. Vestbo, U. Nihlen, T. Sandström, S. Wagers, R. Djukanovic, E. Bel, P. Sterk, F. Chung (London, Southampton, Nottingham, Manchester, Cambridge, United Kingdom; San Diego, United States Of America; Basel, Bern, Switzerland; Krakow, Poland; Amsterdam, Netherlands; Marseille, France; Roma, Catania, Italy; Hvidovre, Denmark; Budapest, Hungary; Hamburg, Ingelheim, Germany; Bergen, Norway; Umeå, Stockholm, Sweden; Maasmechelen, Belgium)
| |
ADEPT-derived, U-BIOPRED validated asthma clinical clusters with Th2 and non-Th2 phenotypes M. Loza, P. Silkoff, V. Susilic, A. Rowe, I. Adcock, C. Auffray, K. F. Chung, R. Djukanovic, P. Sterk, F. Baribaud (Spring House, United States Of America; London, Southampton, United Kingdom; Lyon, France; Amsterdam, Netherlands)
| |